Hepatology Journal
Overview
Publication venue for
- ALTERED EphA2 SIGNALING IN NON-ALCOHOLIC FATTY LIVER DISEASE PROGRESSION. 76:S769-S770. 2022
- EXOSOME SHEDDING IS ASSOCIATED WITH TIME TO PROGRESSION IN NON-RESECTABLE, TRANSPLANT ELIGIBLE HCC UNDERGOING FIRST CYCLE LIVER-DIRECTED THERAPY.. 76:S179-S180. 2022
- HEPATOCELLULAR CARCINOMA SURVEILLANCE BIOMARKERS ALPHA-FETOPROTEIN-L3 AND DES-GAMMA-CARBOXY PROTHROMBIN IN THE CONTEXT OF CURRENT ALPHA-FETOPROTEIN BIOMARKER UTILIZATION IN BRIDGE TO LIVER TRANSPLANT. 76:S471-S471. 2022
- HEPATORENAL SYNDROME AND ACUTE TUBULAR NECROSIS IN CIRRHOSIS HAVE SIMILAR OUTCOMES: A MULTICENTER, ADJUDICATED CONSECUTIVE CASE SERIES FROM THE HRS-HARMONY COLLABORATIVE. 76:S1135-S1136. 2022
- REAL-WORLD SAFETY EXPERIENCE IN PATIENTS WITH ALAGILLE SYNDROME TREATED WITH MARALIXIBAT. 76:S1528-S1528. 2022
- USING THE PREDICTION INTERVAL TO APPLY CLINICAL TRIAL RESULTS AT THE LEVEL OF AN INDIVIDUAL PATIENT. 76:S683-S684. 2022
- A CASE SERIES OF SAFETY AND EFFICACY OF CRUSHED SOFOSBUVIR/VELPATASVIR IN HEPATITIS C INFECTED PATIENTS.. 74:583A-583A. 2021
- CHARACTERISTICS AND OUTCOMES OF SPLENIC INFARCTION IN PATIENTS WITH CIRRHOSIS: NIS DATABASE. 74:1207A-1207A. 2021
- GENE EXPRESSION OF TUMOR SIGNALING PATHWAYS IN EARLY STAGE NAIVE AND LIVER-DIRECTED THERAPY TREATED HEPATOCELLULAR CARCINOMA. 74:643A-644A. 2021
- ELEVATIONS IN PD-1 CORRELATES WITH LOCOREGIONAL TREATMENT RESPONSE AND BRIDGE TO TRANSPLANT SURVIVAL IN HEPATOCELLULAR CARCINOMA PATIENTS AWAITING LIVER TRANSPLANTATION. 72:694A-694A. 2020
- NOVEL QUALITY METRICS OF PSYCHOSOCIAL ASSESSMENT PREDICT HARMFUL ALCOHOL USE AFTER EARLY LIVER TRANSPLANTATION FOR ALCOHOL-ASSOCIATED HEPATITIS. 72:180A-180A. 2020
- SCREENING DIABETIC PATIENTS FOR NAFLD IS COST EFFECTIVE IN THE UNITED STATES: A COMPREHENSIVE ECONOMICAL ANALYSIS. 72:993-994. 2020
- T CELL REPERTOIRE DIVERSITY IN HCV-ASSOCIATED HEPATOCELLULAR CARCINOMA PATIENTS FOLLOWING LOCOREGIONAL THERAPY WHILE WAITLISTED FOR LIVER TRANSPLANTATION. 72:709A-710A. 2020
- WAYS TO ESTIMATE BENEFITS OF TREATMENT FOR NONALCOHOLIC STEATOHEPATITIS IN AN INDIVIDUAL PATIENT. 72:1042-1042. 2020
- ELEVATIONS IN PD-1 CORRELATES WITH LOCOREGIONAL TREATMENT RESPONSE AND BRIDGE TO TRANSPLANT SURVIVAL IN HEPATOCELLULAR CARCINOMA PATIENTS AWAITING LIVER TRANSPLANTATION. 72:694A-694A. 2020
- NOVEL QUALITY METRICS OF PSYCHOSOCIAL ASSESSMENT PREDICT HARMFUL ALCOHOL USE AFTER EARLY LIVER TRANSPLANTATION FOR ALCOHOL-ASSOCIATED HEPATITIS. 72:180A-180A. 2020
- SCREENING DIABETIC PATIENTS FOR NAFLD IS COST EFFECTIVE IN THE UNITED STATES: A COMPREHENSIVE ECONOMICAL ANALYSIS. 72:993-994. 2020
- T CELL REPERTOIRE DIVERSITY IN HCV-ASSOCIATED HEPATOCELLULAR CARCINOMA PATIENTS FOLLOWING LOCOREGIONAL THERAPY WHILE WAITLISTED FOR LIVER TRANSPLANTATION. 72:709A-710A. 2020
- WAYS TO ESTIMATE BENEFITS OF TREATMENT FOR NONALCOHOLIC STEATOHEPATITIS IN AN INDIVIDUAL PATIENT. 72:1042-1042. 2020
- A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF EMRICASAN IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS. 70:43A-44A. 2019
- DONOR SPECIFIC ANTIBODY IN SIMULTANEOUS LIVER-KIDNEY TRANSPLANTATION: PREFORMED CLASS II HLA ANTIBODIES AND ACUTE RENAL AND HEPATIC ALLOGRAFT REJECTION. 70:706A-706A. 2019
- Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?. 69:51-63. 2019
- Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. 70:1521-1530. 2019
- PATTERNS OF ALCOHOL USE AFTER EARLY LIVER TRANSPLANTATION (LT) FOR ALCOHOLIC HEPATITIS (AH): IMPLICATIONS FOR SELECTION AND MONITORING. 70:3A-4A. 2019
- PRE-TREATMENT LYMPHOCYTE STATUS IN HCC PATIENTS ASSOCIATES WITH DEB-TACE RESPONSE AND CORRELATES WITH LIVER SYNTHETIC DYSFUNCTION AND INCREASED REGULATORY IMMUNE CELLS. 70:527A-528A. 2019
- Predicting Low Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The Sustained Alcohol Use Post-Liver Transplant Score. 69:1477-1487. 2019
- Eight Week Hepatitis C Treatment with New Direct Acting Agents Have a Better Safety Profile While Effective in the Geriatric Population without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/Ml. 68:413A-414A. 2018
- Hyperbilirubinemia Promotes Alterations in T Cell Function and Induces Immunotolerogenic Immune Cells in a Mouse Model. 68:940A-941A. 2018
- Modeling Long-Term Outcomes of Early Liver Transplantation (ELT) Vs. Delayed LT (6-Month Wait) for Severe Alcoholic Hepatitis (AH) and Quantifying the Impact of Harmful Alcohol Use Post-LT. 68:656A-656A. 2018
- Necroptosis Contributes to Cell Death of Steatotic Hepatocytes Following Ischaemic Injury. 68:687A-687A. 2018
- Novel Predictors of Alcohol Use after Early Liver Transplantation (LT) for Severe Alcohol-Associated Hepatitis (AAH) and Impact on Long-Term (5-Year) Survival. 68:100A-100A. 2018
- Pre-Transplant Corticosteroids (CS) and Infection Risk after Early Liver Transplantation (LT) for Severe Alcoholic Hepatitis (AH): Good or Bad?. 68:681A-681A. 2018
- Predicting Low-Risk for Sustained Alcohol Use after Early Liver Transplant for Severe Alcoholic Hepatitis: The Salt Score. 68:8A-8A. 2018
- The Efficacy of Tenofivir to Prevent Perinatal Transmission in Chronic Hepatitis B Mothers. A Clinical Perspective Reply. 68:1658-1660. 2018
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. 67:1560-1599. 2018
- Clinical Predictors of Biliary Obstruction at ERCP After Orthotopic Liver Transplantation (OLT). 66:921A-921A. 2017
- High Cure Rate of Hepatitis C in a Primary Care Clinic for People Who Have Limited Access to Specialty Care. 66:845A-845A. 2017
- IL-33/Cyclin D1 Imbalance in Severe Liver Steatosis Predicts Susceptibility to Ischemia Reperfusion Injury in Rats.. 66:1097A-1097A. 2017
- Liver Disease Management TeleECHO Improves Provider Knowledge and Care of Patients. 66:314A-314A. 2017
- Lymphopenia in Waitlist Treatment Naive HCC Patients is Associated with Increased Myeloid-Derived Suppressor Cell Expansion and Decreased Tumor Response to Doxorubicin-Eluting Bead Transarterial Chemoembolization. 66:382A-382A. 2017
- Post-Transplant Outcomes from the Multi-Center American Consortium of Early Liver Transplantation for Alcoholic Hepatitis (ACCELERATE-AH) Study. 66:17A-17A. 2017
- AASLD guidelines for treatment of chronic hepatitis B. 63:261-283. 2016
- Clearance of the hepatitis C virus without treatment occurs more often than traditionally reported. 64:394A-395A. 2016
- Liver Transplantation for "Very Early" Intrahepatic Cholangiocarcinoma: International Retrospective Study Supporting a Prospective Assessment. 64:1178-1188. 2016
- The Expression of RIP3 and IL-33 in Severely Steatotic Rat Livers Correlates with Susceptibility to Liver Failure Following Ischemia Reperfusion Injury.. 64:342A-342A. 2016
- Pre-treatment with TIMP-3 prevents the development of biliary injury in an LPS enhanced ischaemia-reperfusion animal model. 62:616A-616A. 2015
- Prevention of Recurrent Hepatitis C in Liver Transplant (LT) Recipients with Civacir (R) : Preliminary Results on Safety and Efficacy, Including Patients with Renal/Liver Dysfunction. 62:310A-310A. 2015
- Sofosbuvir/Velpatasvir Fixed Dose Combination For The Treatment Of HCV In Patients With Decompensated liver Disease: The Phase 3 ASTRAL-4 Study. 62:1387A-1388A. 2015
- The Association of Pre-Transplant Sarcopenia and Cirrhotic Cardiomyopathy with Postoperative Complications after Liver Transplant.. 62:824A-824A. 2015
- Clinical Outcomes of Hepatitis B Virus Coinfection in a United States Cohort of Hepatitis C Virus-Infected Patients. 60:1871-1878. 2014
- High efficacy and favorable safety profile of Daclatasvir based all oral antiviral therapy in liver Transplant recipients with severe recurrent HCV. 60:1280A-1281A. 2014
- Impaired expression of Type I and Type II interferon-receptors in HCV infected chronic liver disease and liver cirrhosis. 60:1084A-1084A. 2014
- Post-transplant Treatment of Severe Recurrent Hepatitis C (HCV) with Daclatasvir and Sofosbuvir Plus or Minus Ribavirin. 60:542A-543A. 2014
- Prevention of Hepatitis C Virus (HCV) Recurrence with Peri-Transplant Hepatitis C Immune Globulin Combined with Pre-Transplant (Pre-LT) Antiviral Therapy (AVT). 60:206A-207A. 2014
- Shear Wave Elastography and Hepatorenal Index for the Assessment of Liver Fibrosis and Steatosis: a Novel technique and its Predictive Accuracy and Optimal Measurement Location. 60:445A-446A. 2014
- ALT Flares Are Infrequent During the Course of Pregnancy: Prospective Study from the Hepatitis B Research Network (HBRN) Adult Cohort Study. 58:646A-647A. 2013
- Liver transplantation in the morbidly obese: Do the outcomes justify the use of scarce organs?. 58:1031A-1031A. 2013
- EMERGENCE OF YMDD LAMIVUDINE RESISTANCE AFTER TRANSPLANTATION OF ANTI-HBC POSITIVE DONOR LIVERS INTO ANTI-HBC NEGATIVE RECIPIENTS USING LAMIVUDINE MONOTHERAPY PROPHYLAXIS. 54:631A-631A. 2011
- IMPAIRED JAK-STAT SIGNALING OF INTERFERON-alpha IN CHRONICALLY HCV INFECTED LIVER TISSUE. 52:746A-746A. 2010
- LIVER TRANSPLANTATION IN THE SUPER MORBIDLY OBESE: A SINGLE CENTER EXPERIENCE; SECTION OF ABDOMINAL TRANSPLANTATION, OCHSNER CLINIC FOUNDATION, NEW ORLEANS, LA. 50:584A-585A. 2009
- SPLIT RENAL FUNCTION SCANNING DEMONSTRATES LIMITED RECOVERY OF NATIVE RENAL FUNCTION ONE YEAR AFTER COMBINED LIVER AND KIDNEY TRANSPLANTATION IN RECIPIENTS WHO WERE NOT DIALYSIS DEPENDANT. 50:559A-559A. 2009
- SPLIT RENAL FUNCTION SCANNING DEMONSTRATES LIMITED RECOVERY OF NATIVE RENAL FUNCTION ONE YEAR AFTER COMBINED LIVER AND KIDNEY TRANSPLANTATION. 48:337A-337A. 2008
- TISSUE INHIBITOR OF METALLOPROTEINASE-3 (TIMP-3) PROTECTS LIVER HISTOLOGY AND BIOCHEMISTRY IN RATS UNDERGOING SUB-LETHAL TOTAL HEPATIC ISCHEMIA. 48:995A-996A. 2008
Identity
International Standard Serial Number (ISSN)
- 0270-9139